Gossamer Bio, Inc.
Clinical-stage biopharma developing an inhaled therapy for pulmonary hypertension.
GOSS | US
Overview
Corporate Details
- ISIN(s):
- US38341P1021
- LEI:
- Country:
- United States of America
- Address:
- 3115 MERRYFIELD ROW, 92121 SAN DIEGO
- Website:
- https://www.gossamerbio.com/
- Sector:
- Manufacturing
Description
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of its lead investigational product, seralutinib. The company is developing this therapy for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, designed for delivery via a dry powder inhaler. The company's goal is to address the needs of patients with these rare diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gossamer Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gossamer Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gossamer Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
